Clinical trial
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
NCT03523858
Study timeline
Study start (actual)2018-05-28Date precision: day
Registry last updated2026-07-23
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Progressive Multiple Sclerosis (PMS)unresolved
Interventions
OcrelizumabDRUG · verified · RxNorm: ocrelizumab
Sponsors & collaborators
Hoffmann-La Rochelead sponsor
Mapped research locations
DublinIreland2MilanLombardy, Italy2BostonMassachusetts, United States1ChicagoIllinois, United States1St LouisMissouri, United States1TorontoOntario, Canada1San AntonioTexas, United States1San FranciscoCalifornia, United States1BarcelonaSpain1SeattleWashington, United States1CincinnatiOhio, United States1TampaFlorida, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03523858 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.